- About Us
- Advertise
- Contact Us
- Editorial Info
- Editorial Contacts
- Editorial Advisory Board
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Featured Content
Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?
Mar 4th 2024
Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.
Training for Operational Excellence
Dec 3rd 2023
The bio/pharmaceutical industry is struggling with the challenge of staffing and training.
Billions of Reasons to be Buoyant
Sep 2nd 2023
Pharma's ability to continually reinvent itself will be critical in growing future business operations.
Unpacking Amgen v. Sanofi
Aug 31st 2023
Exploring the state of pharma patents following the Supreme Court’s Amgen v. Sanofi decision.
Latest Videos
Latest News
Lantheus Acquires Meilleur Technologies, PET Imaging Agent
July 15th 2024
The acquisition provides Lantheus with worldwide exclusive rights to ß amyloid PET imaging agent, NAV-4694, for its Alzheimer’s disease diagnostic and treatment portfolio.
Thermo Fisher Scientific Expands Proteomics Services with Olink Acquisition
July 13th 2024
Thermo Fisher will add Olink to its Life Sciences Solutions business.
Pfizer and Evotec Partner for Drug Discovery
July 12th 2024
Pfizer and Evotec will focus on early discovery research for therapeutics targeting metabolic and infectious diseases.
uniQure to Sell Its Commercial Gene Therapy Manufacturing Operations in Massachusetts to Genezen
July 10th 2024
The acquisition of uniQure’s Lexington, Mass., manufacturing operations will boost Genezen’s late-phase and commercial gene therapy development and manufacturing services.
Cell-Free Protein Synthesis Technology to be Made More Accessible Through LenioBio and Labscoop Partnership
July 4th 2024
LenioBio and Labscoop's new strategic partnership is aimed at increasing access to scalable cell-free protein synthesis technology across North America.
Aurigene to Provide Cell Therapy Discovery Services to Edity to Support Clinical Development
July 2nd 2024
This collaboration aims to support and accelerate clinical development of advanced and novel technologies.
AbbVie Advances Inflammatory Disease Portfolio with Celsius Therapeutics Acquisition
June 29th 2024
This acquisition will give AbbVie acces to Celsius Therapeutics' lead drug candidate, CEL383, a potential first-in-class anti-TREM1 antibody for treating IBD.
Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets
June 28th 2024
Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.
Roche and Ascidian Therapeutics Collaborate on Treatments for Neurological Diseases
June 18th 2024
The research collaboration and licensing agreement will focus on the discovery and development of RNA exon editing therapeutics.
Pushing Boundaries to Revolutionize Chronic Inflammation Therapy
June 14th 2024
Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.